Table 1. IC₅₀ values and p53 status of the cell lines used in this study.

Cell line	IC50 cisplatin (μM)a	IC50 combination (μM)b	Enhancement ratioc	P53 statusd
Tera	0.69±0.11	0.07±0.01	9.9	wt/wt
Tera-CP	2.14±0.17	0.11±0.02	19.5	wt/wt
833KE	1.04±0.10	0.13±0.03	8.0	wt/wt
Scha	2.91±0.84	0.28±0.08	10.4	wt/wt
2102EP	4.05±0.66	0.39±0.21	10.4	wt/wt
NCCIT	2.15±0.34	2.25±0.59	1.0	mt/−

^aThe IC₅₀ (drug concentration reducing cell survival by 50%) for cisplatin was calculated from the graphs in Figure 6a and Supplementary Figures 4a and b. The mean IC₅₀±S.D. was determined in three experiments, each performed in quadruplicate.

^bThe IC₅₀ (drug concentration reducing cell survival by 50%) for cisplatin in combination with 1 μM Nutlin-3 was calculated from the graphs in Figure 6a and Supplementary Figures 4a and b. The mean IC₅₀±S.D. was determined in three experiments, each performed in quadruplicate.

^cNutlin-3 enhancement ratios were calculated by dividing the IC₅₀ for cisplatin alone by the IC₅₀ for the combination with cisplatin and 1 μM Nutlin-3.

^dThe p53 status of the cells was previously described^{3, 30}